$1.99
0.073.65%
At Close: -
$2.01
0.021.01%
After Hours: 5:48 PM EDT
15 minutes delayed
Comments
Loading...
Exagen
XGNNASDAQ
Exagen (NASDAQ:XGN) Stock, Analyst Ratings, Price Targets, Forecasts
Exagen Inc has a consensus price target of $9 based on the ratings of 4 analysts. The high is $17 issued by Keybanc on May 13, 2022. The low is $5 issued by BTIG on March 22, 2023. The 3 most-recent analyst ratings were released by Cantor Fitzgerald on May 14, 2024, September 26, 2023, and August 22, 2023, respectively. With an average price target of $6.33 between Cantor Fitzgerald, there's an implied 215.09% upside for Exagen Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Cantor Fitzgerald
BTIG
Canaccord Genuity
Keybanc
1calculated from analyst ratings
Analyst Ratings for Exagen
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/14/2024 | Buy Now | 248.26% | Cantor Fitzgerald | Ross Osborn | $5 → $7 | Maintains | Overweight | Get Alert |
| 09/26/2023 | Buy Now | 198.51% | Cantor Fitzgerald | Ross Osborn | → $6 | Reiterates | Overweight → Overweight | Get Alert |
| 08/22/2023 | Buy Now | 198.51% | Cantor Fitzgerald | Ross Osborn | → $6 | Reiterates | Overweight → Overweight | Get Alert |
| 05/16/2023 | Buy Now | 198.51% | Cantor Fitzgerald | Ross Osborn | → $6 | Reiterates | Overweight → Overweight | Get Alert |
| 03/22/2023 | Buy Now | 148.76% | BTIG | Mark Massaro | $6 → $5 | Maintains | Buy | Get Alert |
| 11/17/2022 | Buy Now | 248.26% | BTIG | Mark Massaro | $10 → $7 | Maintains | Buy | Get Alert |
| 11/15/2022 | Buy Now | 248.26% | Canaccord Genuity | Kyle Mikson | $8 → $7 | Maintains | Buy | Get Alert |
| 05/13/2022 | Buy Now | 745.77% | Keybanc | Paul Knight | $20 → $17 | Maintains | Overweight | Get Alert |
| 03/25/2022 | Buy Now | 895.02% | Keybanc | Paul Knight | $30 → $20 | Maintains | Overweight | Get Alert |
| 11/11/2021 | Buy Now | 1392.54% | Keybanc | Paul Knight | — | Maintains | Overweight | Get Alert |
FAQ
What is the target price for Exagen (XGN) stock?
The latest price target for Exagen (NASDAQ:XGN) was reported by Cantor Fitzgerald on May 14, 2024. The analyst firm set a price target for $7.00 expecting XGN to rise to within 12 months (a possible 248.26% upside). 3 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Exagen (XGN)?
The latest analyst rating for Exagen (NASDAQ:XGN) was provided by Cantor Fitzgerald, and Exagen maintained their overweight rating.
When was the last upgrade for Exagen (XGN)?
There is no last upgrade for Exagen
When was the last downgrade for Exagen (XGN)?
There is no last downgrade for Exagen.
When is the next analyst rating going to be posted or updated for Exagen (XGN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Exagen, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Exagen was filed on May 14, 2024 so you should expect the next rating to be made available sometime around May 14, 2025.
Is the Analyst Rating Exagen (XGN) correct?
While ratings are subjective and will change, the latest Exagen (XGN) rating was a maintained with a price target of $5.00 to $7.00. The current price Exagen (XGN) is trading at is $2.01, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.